Program
pembrolizumab
Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Urinary Bladder Neoplasms, led by 8 companies.
Drug pagePembrolizumab: every studyMany companies study it; this page follows only the 148 they lead. All 1,133 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 13824 open or running | phase 4since Oct 19, 2018 | Feb 10, 2011 | Nov 20, 2026phase 3 · NCT04634877 |
| Novartisits history only | 30 open or running | phase 2since May 15, 2019 | Dec 12, 2013 | none ahead |
| PDS Biotechnologyits history only | 20 open or running | phase 3since Jan 14, 2025 | Feb 5, 2020 | none ahead |
| AGO Researchits history only | 11 open or running | phase 2since May 11, 2023 | May 11, 2023 | Oct 30, 2027phase 2 · NCT05903833 |
| EverNov Medicines (Zhuhai Hengqin)its history only | 10 open or running | phase 2since Dec 29, 2020 | Dec 29, 2020 | none ahead |
| Mediclinic Middle Eastits history only | 10 open or running | phase 2since Mar 14, 2019 | Mar 14, 2019 | none ahead |
| NovoCureits history only | 11 open or running | phase 3since Aug 13, 2024 | Aug 13, 2024 | Apr 2029phase 3 · NCT06556563 |
| TiumBioits history only | 11 open or running | phase 2since Feb 20, 2023 | Feb 20, 2023 | Dec 2026phase 2 · NCT05784688 |
Also a collaborator on its studies: Eisai, Pfizer, Astellas Pharma, Novotech (Australia) Pty and Medidata Solutions.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 52 studies since Dec 13, 2018.
- Feb 4, 2022Phase 3 study in Colorectal NeoplasmsMerck · NCT05239741 · 100 enrolled · China
- Feb 20, 2023TiumBio’s first study: phase 2 study in Biliary Tract NeoplasmsNew to TiumBioTiumBio · NCT05784688 · 140 planned · United States, Korea, Republic of
- May 11, 2023AGO Research’s first study: phase 2 study in Vulvar NeoplasmsNew to AGO ResearchAGO Research · NCT05903833 · 42 planned · Germany
- Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungMerck · NCT06099782 · 147 enrolled · United States, Argentina, Australia and more
- Aug 13, 2024NovoCure’s first study: phase 3 study in GlioblastomaNew to NovoCureNovoCure · NCT06556563 · 741 enrolled · United States, Canada, Czechia and more
- Jan 14, 2025Phase 3 study in Head and Neck NeoplasmsPDS Biotechnology · NCT06790966 · 12 enrolled · United States
- Dec 11, 2025Phase 2 study in NeoplasmsMerck · NCT07302347 · 20 planned · Japan
- Aug 28, 2026Phase 4 study in NeoplasmsMerck · NCT07801027 · 150 planned
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03833167 · “The study stopped due to futility”
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT03834493 · “The study stopped due to futility”
- Sep 28, 2026Phase 3 study terminatedStudy stoppedNCT04191096 · “The study stopped due to futility”
- Oct 2, 2026Primary completion moved from 2026-11-06 to 2027-02-12Date moved laterphase 2 · +3 months · NCT03407144
- Oct 23, 2026Primary completion moved from 2026-07-31 to 2028-07-31Date moved laterphase 3 · +24 months · NCT03711032
- Nov 18, 2026Phase 2 study terminatedStudy stoppedNCT04428151 · “Business Reasons”
Ahead
- Nov 20, 2026Primary completion: phase 3 study in Endometrial NeoplasmsMerck · NCT04634877
- Dec 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsTiumBio · NCT05784688
- Jan 31, 2027Primary completion: phase 3 study in Urinary Bladder NeoplasmsMerck · NCT04241185
- May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 148 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07801027Neoplasms | 4 | Not yet recruiting | Merck | Jan 31, 2030 | 150 |
| NCT07302347Neoplasms · Japan | 2 | Recruiting | Merck | Mar 30, 2029 | 20 |
| NCT06790966Head and Neck Neoplasms · United States | 3 | Terminated | PDS Biotechnology | Aug 25, 2026 | 12 |
| NCT06556563Glioblastoma · United States, Canada, Czechia and more | 3 | Active, not recruiting | NovoCure | Apr 2029 | 741 |
| NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Apr 9, 2025 | 147 |
| NCT05903833Vulvar Neoplasms · Germany | 2 | Recruiting | AGO Research | Oct 30, 2027 | 42 |
| NCT05784688Biliary Tract Neoplasms · United States, Korea, Republic of | 2 | Recruiting | TiumBio | Dec 2026 | 140 |
| NCT05239741Colorectal Neoplasms · China | 3 | Active, not recruiting | Merck | Sep 19, 2028 | 100 |
| NCT05173987Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | May 27, 2027 | 280 |
| NCT05116189Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Mar 5, 2025 | 643 |
| NCT05008224Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Oct 11, 2023 | 146 |
| NCT04956692Carcinoma, Non-Small-Cell Lung · United States, Brazil, France and more | 3 | Completed | Merck | Apr 4, 2023 | 531 |
| NCT04934722Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Merck | Oct 31, 2022 | 186 |
| NCT04924062Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 3 | Completed | Merck | Dec 15, 2022 | 158 |
| NCT04907227Prostatic Neoplasms · China | 3 | Terminated | Merck | Aug 3, 2022 | 81 |
| NCT04895358Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Apr 24, 2026 | 342 |
| NCT04882241Stomach Neoplasms · China | 3 | Completed | Merck | Feb 16, 2024 | 120 |
| NCT04875195Hodgkin Disease · United States, Brazil, Canada and more | 2 | Completed | Merck | Dec 14, 2023 | 66 |
| NCT04865289Endometrial Neoplasms · China | 3 | Completed | Merck | Oct 2, 2023 | 130 |
| NCT04859582Stomach Neoplasms · China | 3 | Withdrawn | Merck | Nov 29, 2024 | 0 |
| NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Sep 27, 2024 | 563 |
| NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Merck | Jan 27, 2025 | 160 |
| NCT04700124Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Oct 27, 2025 | 808 |
| NCT04699643Advanced Solid Tumors · China | 2 | UNKNOWN | EverNov Medicines (Zhuhai Hengqin) | Jun 2023 | 80 |
| NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 29, 2024 | 895 |
| NCT04634877Endometrial Neoplasms · United States, Argentina, Austria and more | 3 | Active, not recruiting | Merck | Nov 20, 2026 | 990 |
| NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Oct 28, 2027 | 672 |
| NCT04489888Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 4 | Completed | Merck | Feb 20, 2023 | 101 |
| NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more | 2 | Terminated | Merck | May 31, 2024 | 408 |
| NCT04380636Lung Neoplasms · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | May 5, 2027 | 870 |
| NCT04317066Lymphoma, B-Cell · Japan | 1 | Completed | Merck | Apr 11, 2024 | 7 |
| NCT04260126Head and Neck Neoplasms · United States, Ireland, Puerto Rico and more | 2 | Completed | PDS Biotechnology | May 14, 2025 | 95 |
| NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Terminated | Merck | Aug 19, 2025 | 480 |
| NCT04241185Urinary Bladder Neoplasms · United States, Australia, Chile and more | 3 | Active, not recruiting | Merck | Jan 31, 2027 | 520 |
| NCT04221945Uterine Cervical Neoplasms · United States, Australia, Austria and more | 3 | Completed | Merck | Jan 7, 2025 | 1,060 |
| NCT04210115Esophageal Squamous Cell Carcinoma · United States, Argentina, Belgium and more | 3 | Completed | Merck | Jan 21, 2026 | 703 |
| NCT04191096Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Austria and more | 3 | Terminated | Merck | Oct 31, 2022 | 1,251 |
| NCT04153565Mesothelioma · Japan | 1 | Completed | Merck | Sep 21, 2022 | 19 |
| NCT04123366Solid Tumors · United States, Argentina, Australia and more | 2 | Completed | Merck | Jun 8, 2026 | 333 |
| NCT04003636Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more | 3 | Completed | Merck | Dec 15, 2022 | 1,069 |
| NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Merck | Aug 11, 2023 | 422 |
| NCT03968419Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Terminated | Novartis | Apr 20, 2022 | 88 |
| NCT03950674Carcinoma, Non-Small-Cell Lung · Japan | 3 | Completed | Merck | May 20, 2019 | 40 |
| NCT03933449Esophageal Neoplasms · China | 3 | Completed | Merck | Feb 13, 2019 | 123 |
| NCT03924895Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Jun 6, 2025 | 595 |
| NCT03924869Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | Merck | Jun 11, 2024 | 448 |
| NCT03924856Urinary Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Jan 26, 2026 | 907 |
| NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Oct 2, 2023 | 842 |
| NCT03881111Esophageal Neoplasms · China | 3 | Withdrawn | Merck | May 11, 2021 | 0 |
| NCT03879174Breast Cancer Female · United Arab Emirates | 2 | UNKNOWN | Mediclinic Middle East | Aug 1, 2022 | 25 |
| NCT03875092Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Merck | Sep 30, 2020 | 125 |
| NCT03867084Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 20, 2025 | 959 |
| NCT03850444Carcinoma, Non-Small-Cell Lung | 3 | Completed | Merck | Sep 4, 2018 | 262 |
| NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 14, 2022 | 793 |
| NCT03834506Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Jun 20, 2022 | 1,030 |
| NCT03834493Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Merck | Dec 12, 2022 | 1,244 |
| NCT03833167Carcinoma, Squamous Cell · United States, Argentina, Australia and more | 3 | Terminated | Merck | Jun 28, 2024 | 450 |
| NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Merck | Oct 28, 2024 | 611 |
| NCT03783078Carcinoma, Merkel Cell · United States, Australia, Canada and more | 3 | Completed | Merck | Feb 15, 2022 | 55 |
| NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more | 2 | Completed | Merck | Oct 11, 2023 | 103 |
How it is read
Names in the registry
- “Pembrolizumab”, 124 entries
- “pembrolizumab”, 29 entries
- “Pembrolizumab 200 mg”, 7 entries
- “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
- “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 30 studies
- Melanoma, 14 studies
- Squamous Cell Carcinoma of Head and Neck, 10 studies
- Stomach Neoplasms, 10 studies
- Urinary Bladder Neoplasms, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.